Author of

• 20165

  +

  P1.16 - Surgery (ID 702)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Surgery
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22819

    +

    P1.16-017 - Middle Term Survival Outcome of Single Port Video Assisted Thoracoscopic Anatomic Lung Resection: Two Center Experience (ID 9346)

    09:30 - 09:30  |  Author(s): E. Fieira
    • Abstract
    • Slides

    Background:
    Lung cancer is the leading cause of cancer-related death all over the world. Surgery is the treatment choice for patients with non -small cell lung cancer stage I through IIIA. Dr McKenna first described video-assisted thoracoscopic lobectomy (VATS) in 1994. Thereafter, VATS is like mushrooming rapidly spreading all over the world. During recent two decades, minimal invasive thoracoscopic anatomic lung resection with lymph node dissection is now widely accepted as a safe and oncological sound treatment option. The move forward minimal invasive VATS has driven the development of sophisticated instruments and different concepts to cope with the demanding need of working through smaller and fewer incision wounds. Until recently, single port VATS (SPVATS) is now being used for a growing number of applications, even including major lung resection for lung cancer. However, majority of single port VATS related studies are only related to its perioperative outcomes and feasibility. There are still few studies reporting its oncological results. The objective of this study is not only to evaluate the perioperative outcome but also to discuss the middle term oncological outcome in two medical centers’ experience
    
    Method:
    We retrospectively reviewed patients who underwent SPVATS anatomic resections between January 2014 and February 2017 in Coruña University Hospital and Minimally Invasive Thoracic Surgery Unit (Spain) and Chang Gung Memorial Hospital (Taiwan). Survival outcomes were assessed by pathological stage of American Joint Committee on Cancer (AJCC) 7th and 8th classifications
    
    Result:
    307 patients were finally enrolled in this study. The 2-year disease free survival and 2-year overall survival of the cohort were 80.6 %and 93.4% for 1A , 68.1 %and 84.3% for 1B , 67.5 % and 72.3% for 2A, 18.4% and %49.6 % for 2B , 52.2 % and 61.6 % for 3A, respectively forAJCC 7th classifications. For AJCC 8th classifications, there were 92.3% and 100% for 1A1, 73.7% and 91.4% for 1A2 , 75.2 % and 93.4% for 1A3, 60.9 %and 85.5% for 1B, 55.6% and 72.7 %for 2A, 60.5%and 84.3 % for 2B, 45.4 % and 62.4% for3A
    
    Conclusion:
    Our preliminary results revealed that SPVATS anatomic resection achieves non-compromised middle term survival outcomes for early stage lung cancer. For advanced stage NSCLC patients, further evaluation was warranted
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.